Document is current
Any future updates will be listed below
-
Authors
Brembeck, Petra
Andersson-Assarsson, Johanna C.
Peltonen, Markku
Taube, Magdalena
Sjöholm, Kajsa
Ahlin, Sofie
Adméus, Lucas
Konttinen, Hanna
Larsson, Ingrid
Engström, My
Henning, Björn
Carlsson, Lena M. S.
Svensson, Per-Arne
-
Funding
Funding for this research was provided by:
Stiftelserna Wilhelm och Martina Lundgrens (2025-SA-4942)
Stiftelserna Wilhelm och Martina Lundgrens (2025-SA-4961)
Adlerbert Research Foundation
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-1006404)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-1005957)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-1006165)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-1006182)
Health & Medical Care Committee of the Region Västra Götaland (VGFOUFBD-1004644)
Vetenskapsrådet (2021-01496)
Vetenskapsrådet (2020-01303)
The Swedish Heart and Lung Foundation (20240397)
Felix Neuberghs Foundation
University of Gothenburg
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 25 March 2026
First Online: 18 April 2026
Declarations
:
: The study protocol was approved by seven ethics review boards in Sweden: Gothenburg, Karolinska Institute, Linköping, Lund, Umeå, Uppsala, and Örebro. All patients provided written or oral informed consent. Reference numbers: 184–90, S604-01, T508-17, and 2022–03879-01.
: All authors consent for publication.
: K.S.: Speaker honoraria from AstraZeneca and Encore Medical Education. M.T.: Stocks in Umecrine AB and has a patent licensed to Umecrine AB. L.M.S.C.: Consultancy for AstraZeneca. All other: None reported.
